http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021533085-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-07 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 |
| filingDate | 2019-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2021533085-A |
| titleOfInvention | 1,2,4-Triazole derivative as a tankylase inhibitor |
| abstract | The present invention comprises compounds of formula (I), their tautomers, steric isomers, pharmaceutically acceptable salts, and prodrugs, processes for their preparation, pharmaceutical compositions containing such compounds. Also with respect to their use in treatment, in the formula, dashed lines indicate arbitrary bonds, X is halogen (ie, F, Cl, Br, I), C 1-6 alkyl (eg, C 1-3 alkyl). , C 1-6 haloalkyl (eg, C 1-3 haloalkyl), C 1-6 alkoxy (eg, C 1-3 alkoxy), -CN, -NO 2 , -N (R) 2, and -SO 2 R. One or more (eg, one, two, in the formula, where each R is independently selected from H or C 1-6 alkyl, eg, H or C 1-3 alkyl). Or a 5- or 6-membered unsaturated heterocyclic group optionally substituted with a substituent (or 3), C 1-6 alkyl (preferably C 1-3 alkyl), C 1-6 haloalkyl (eg C). 1-3 haloalkyl), and C optionally substituted with one or more (eg, 1 or 2) substituents independently selected from C 1-6 alkoxy (eg, C 1-3 alkoxy). 3-5 cycloalkyl groups, or halogens (ie, F, Cl, Br, I), C 1-6 alkyl (eg, C 1-3 alkyl), C 1-6 haloalkyl (eg, C 1-3 haloalkyl). , And an aryl group optionally substituted with one or more (eg, 1, 2, or 3) substituents independently selected from C 1-6 alkoxy (eg, C 1-3 alkoxy). , Y represents halogen (ie, F, Cl, Br, I), C 1-6 alkyl (eg, C 1-3 alkyl), C 1-6 haloalkyl (eg, C 1-3 halo alkyl), and. Aryl or heteroaryl optionally substituted with one or more (eg, 1, 2, or 3) substituents independently selected from C 1-6 alkoxy (eg, C 1-3 alkoxy). group independently, C 1-6 alkyl (preferably, C 1-3 alkyl), C 1-6 haloalkyl (e.g., C 1-3 haloalkyl), and C 1-6 alkoxy (e.g., C 1-3 alkoxy) A 5- or 6-membered saturated heterocyclic group optionally substituted with one or more (eg, one, two, or three) substituents selected in the above, or C 1-6 alkyl ( Preferably, one or more independently selected from C 1-3 alkyl), C 1-6 haloalkyl (eg, C 1-3 haloalkyl), and C 1-6 alkoxy (eg, C 1-3 alkoxy). Represents a C 3-6 cycloalkyl group optionally substituted with (eg, 1 or 2) substituents, where Z is a halogen (ie, F, Cl, Br, I), C 1-6 alkyl (ie). For example, C 1-3 alkyl), C 1-6 haloalkyl (eg, C 1-3 haloalkyl), C 1-6 alkoxy (eg, C 1-3 alkoxy), -CN, -NO 2 , -N (R). ) 2, and -SO 2 R (wherein each R is independently, H or C 1-6 alkyl, for example, one or more independently selected from H or C 1-3 alkyl) ( For example, an aryl group optionally substituted with one, two, or three) substituents, or a halogen (ie, F, Cl, Br, I), C 1-6 alkyl (eg, C 1-3). Alkyl), C 1-6 haloalkyl (eg, C 1-3 haloalkyl), C 1-6 alkoxy (eg, C 1-3 alkoxy), -CN, -NO 2 , -N (R) 2 , and -SO. 2 One or more (eg, one, two) independently selected from two Rs (in the formula, where each R is independently H or C 1-6 alkyl, eg, H or C 1-3 alkyl). Represents an unsaturated 5- to 10-membered monocyclic or bicyclic heterocyclic group optionally substituted with one or three) substituents. These compounds find specific use in the treatment and / or prevention of diseases or disorders that respond to inhibition of tankylase 1 and / or 2, eg, disorders mediated by tankylase 1 and / or 2 such as cancer. [Chemical 1] |
| priorityDate | 2018-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 92.